Company
(location)

Type of
financing

Number of
shares, units
or warrants
(M)

Amount
raised
(M)

Investors; placement agents; details

Date

TOTAL: $1,644.17M

Acasti Pharma Inc. (Laval, Quebec)

Private placement of units

N/A

$7.50

Acasti Pharma received a receipt for a preliminary short form prospectus for a proposed offering of units for minimum gross proceeds of C$6.5M and maximum gross proceeds of C$10M (US$7.5M); the offering will be conducted on a "commercially reasonable best efforts" basis through an agency syndicate led by Echelon Wealth Partners Inc.

12/7/16

Agile Therapeutics Inc. (Princeton, N.J.)

New Jersey's Technology Business Tax Certificate Transfer Program

N/A

$3.00

Agile Therapeutics received net proceeds of approximately $3M in nondilutive financing through New Jersey's Technology Business Tax Certificate Transfer Program

12/2/16

Amicus Therapeutics Inc. (Cranbury, N.J.)

Private placement of convertible senior notes due 2023

Convertible senior notes due 2023

$250.00

Amicus priced its $225M private placement of convertible senior notes due 2023; the notes will bear 3% interest annually and carry an initial conversion price of about $6.12 per share of Amicus' common stock, representing a premium of about 27.5% over the last reported sale price of the company's common stock on Dec. 15; it also exercised the overallotment option for an additional $25M in notes

12/19/16

Antibe Therapeutics Inc. (Toronto)

Private placement

N/A

$2.40

Antibe raised about $2.4M with completion of the first tranche of a private placement

12/19/16

Appili Therapeutics Inc. (Halifax, Nova Scotia)

Private placement

N/A

$2.20

Appili raised about $2.2M in its oversubscribed private placement financing; the raise included investments from current investors, including Innovacorp, and new investors

12/23/16

Canabo Medical Inc. (Vancouver, British Columbia)

Private placement

6S

$8.40

Canabo Medical placed 6M shares at $1.40 each with Aphria Inc., which will then own approximately 16.6% of the total issued and outstanding common shares; the placement will be subject to an aggregate finders' fee equal to 5% of the gross proceeds payable to Haywood Securities Inc., Powerone Capital Markets Ltd., and Clarus Securities Inc.; Haywood will be granted an overallotment option to sell additional common shares equal to 15% of the size of the offering

12/8/16

Catalent Pharma Solutions Inc. (subsidiary of Catalent Inc.; Somerset, N.J.)

Private placement

Senior notes due 2024

$405.00

Catalent Pharma priced a private offering of €380M (US$405M) aggregate principal amount of 4.75% senior unsecured notes due 2024

12/5/16

Cel-Sci Corp. (Vienna, Va.)

Private placement

34S and W

$4.25

Cel-Sci agreed to sell 34M shares of common stock and warrants to purchase common stock at $0.125; the warrants consist of 17M series CC warrants to purchase 17M shares of common stock at an exercise price of $0.20 each, 34M series DD warrants to purchase 34M shares of common stock at an exercise price of $0.18 per share, and 34M series EE warrants to purchase 34M shares of common stock at an exercise price of $0.18 per share; Rodman & Renshaw is exclusive placement agent

12/5/16

Celsion Corp. (Lawrenceville, N.J.)

Registered direct offering

5.2S

$1.80

Celsion entered a definitive agreement with several institutional investors to purchase an aggregate of about $1.8M of shares of common stock in a registered direct offering; the company agreed to sell about 5.2M shares at 35 cents apiece; Investors also will receive, for each share of common stock, a warrant to purchase a share of common stock; Rodman & Renshaw, a unit of H.C. Wainwright & Co. LLC, is acting as exclusive placement agent

12/21/16

Cytrx Corp. (Los Angeles)

Registered direct offering

N/A

$8.10

Cytrx entered securities purchase agreements with existing institutional investors to purchase shares of common stock at 42 cents each in a registered direct offering with gross proceeds of $8.1M

12/14/16

Enumeral Biomedical Holdings Inc. (Cambridge, Mass.)

Warrant exercise

6.86W

$3.40

Enumeral Biomedical Holdings received gross proceeds of approximately $3.4M in connection with the completion of its previously announced issuer tender offer; warrant holders elected to amend and exercise 6.86M of the warrants at a reduced exercise price of 50 cents per warrant; warrant holders who elected to participate received four shares of Enumeral common stock for each warrant exercised

12/14/16

Galectin Therapeutics Inc. (Norcross, Ga.)

Private placement

N/A

$3.00

Completed a $3M private placement of its common stock

12/30/16

Galectin Therapeutics Inc. (Norcross, Ga.)

Series B-3 preferred stock sale

2.8S

$1.00

Closed a sale of its series B-3 preferred stock to 10X Fund LP; together, one existing investor and one current investor purchased about 2.8M shares in the common stock placement at above-market price and received an unspecified number of warrants for common stock exercisable at $5 per share; 10X Fund also received warrants for common stock exercisable at $3 per share

12/30/16

Inspyr Therapeutics Inc. (Westlake Village, Calif.)

Private placement of shares of convertible preferred stock and warrants

N/A

$1.00

Inspyr entered into definitive securities purchase agreements with institutional and accredited investors, for the private placement of shares of convertible preferred stock and warrants to purchase shares of common stock resulting in gross proceeds of approximately $1M

12/13/16

Knight Therapeutics Inc. (Montreal)

Bought deal financing

7.5S

$10.00

Knight Therapeutics entered a bought deal agreement with a syndicate of underwriters led by GMP Securities L.P. and Cormark Securities Inc. who agreed to purchase 7.5M common shares at $10 each for gross proceeds of $75M; the underwriters will have the option, exercisable for 30 days after the closing date, to acquire up to an aggregate of 1.125M additional shares ($11.25M) at the offering price

12/7/16

Knight Therapeutics Inc. (Montreal)

Bought deal financing

N/A

$100.00

Knight Therapeutics completed its bought deal offering for gross proceeds of $100M

12/23/16

Living Cell Technologies Ltd. (Auckland, New Zealand)

Private placement

74.1S

$6.30

Living Cell completed the placement of approximately 74.1M shares to institutional and professional investors, priced at 8.5 cents apiece, to raise $6.3M; Hunter Capital Advisors acted as sole lead manager for the placement

12/1/16

Nabriva Therapeutics AG (Vienna)

Rights offering

0.588S

$25.00

Nabriva Therapeutics closed a rights offering of up to 588,127 common shares, including those represented by American depositary shares (ADSs), to shareholders and ADS holders as of Nov. 29; holders of the company's ADSs received 0.276 ADS rights for each ADS owned on that record date and the right to subscribe for and purchase one new ADS at the U.S. dollar equivalent of €4.014 (US$4.25) per ADS, through Dec. 12; holders of common shares have the right, through Dec. 14, to subscribe for and purchase 0.276 new shares for each common share owned at a price of €40.14 (US$42.55) apiece

12/1/16

Northwest Biotherapeutics Inc. (Bethesda, Md.)

Registered direct offering

28.6S and W for 14.3S

$10.00

Northwest entered definitive agreements with institutional investors for a registered direct offering with gross proceeds of $10M; the company will sell approximately 28.6M shares of common stock at 35 cents per share; the investors will also receive warrants to purchase up to about 14.3M shares of common stock with an exercise price of 35 cents per share and an exercise period of five years; Chardan Capital Markets LLC acted as the exclusive placement agent

12/21/16

Ohr Pharmaceuticals Inc. (New York)

Registered direct offering

3.885S and W

$7.77

Ohr priced a $7.77M registered public offering of an aggregate of 3.88M shares of common stock at $2 per share; investors will also receive series A warrants to purchase up to an aggregate of 1.94M shares of common stock with an exercise price of $2.75 per share and series B warrants to purchase up to an aggregate of 3.885M shares of common stock with an exercise price of $3 per share; H.C. Wainwright & Co. LLC is acting as exclusive placement agent

12/9/16

Oncobiologics Inc. (Cranbury, N.J.)

Note and warrant purchase agreement

N/A

$8.35

Oncobiologics entered a note and warrant purchase agreement with existing investors providing for the issuance and sale of up to $10M of senior secured promissory notes and five-year warrants to acquire an aggregate of 2.3M shares of company stock at an exercise price of $3 each; at the initial closing, the company issued $8.35M aggregate principal amount of notes and about 1.9M warrants, and it may issue up to $1.65M of additional notes and 379,500 warrants in additional closings over 90 days from the date of the agreement

12/27/16

Pharming Group NV (Leiden, the Netherlands)

Rights issue and other financing

N/A

$111.80

Pharming Group closed a new financing round, comprising three financial instruments and a rights issue, providing a total of €104M (US$111.8M)

12/8/16

Portola Pharmaceuticals Inc. (South San Francisco)

Loan

N/A

$50.00

Portola signed a $50M loan agreement with Bristol-Myers Squibb Co. (BMS) and Pfizer Inc., both of New York; BMS and Pfizer will each loan Portola $25M; the principal and interest will be repaid primarily through royalties on Andexxa commercial sales

12/20/16

Q Biomed Inc. (New York)

Convertible debentures

N/A

$1.50

Q Biomed inked a definitive agreement with Yorkville Advisors Global for up to $4M of convertible debentures, closing an initial tranche of $1.5M

12/1/16

Rasna Therapeutics Inc. (New York)

Private placement

3.4S

$2.00

Rasna closed a private placement to accredited investors of an aggregate 3.4M shares of common stock at 60 cents per share for gross proceeds of about $2M

12/28/16

Redhill Biopharma Ltd. (Tel Aviv, Israel)

Registered direct offering

1.5ADS and W for 0.73ADS

$15.00

Redhill offered 1.5M ADSs and warrants to purchase 731,708 ADSs for proceeds of about $15M in a registered direct offering done concurrently with a public offering that raised $24.4M; Roth Capital Partners is acting as placement agent

12/22/16

Strongbridge Biopharma plc (Trevose, Pa.)

Private placement

N/A

$35.00

Strongbridge (formerly Cortendo plc) raised gross proceeds of $35M through an equity financing; CAM Capital and Vivo Capital led the financing, with additional participation from Broadfin Capital, Boxer Capital and Healthcap, as well as several new and existing institutional and individual investors; Stifel is acting as the lead placement agent; JMP Securities is acting as the lead co-placement agent; H.C. Wainwright & Co. and Arctic Securities are acting as co-placement agents

12/30/16

Strongbridge Biopharma plc (Trevose, Pa.)

Private placement of stock and warrants

14S

$35.00

Strongbridge is placing 14M shares at $2.50 each and warrants to purchase 7M shares to raise $35M in a financing led by CAM Capital and Vivo Capital, with additional participation from Broadfin Capital, Boxer Capital of the Tavistock Group and Healthcap, as well as several new and existing institutional and individual investors; Stifel is acting as the lead placement agent, JMP Securities is acting as the lead co-placement agent and H.C. Wainwright & Co. and Arctic Securities are acting as co-placement agents

12/27/16

Sucampo Pharmaceuticals Inc. (Rockville, Md.)

Convertible senior notes offering due 2021

N/A

$225.00

Sucampo intends to offer, subject to market and other conditions, $225M principal amount of convertible senior notes due 2021 in a private offering to qualified institutional buyers; the company also expects to grant the initial purchasers of the notes a 13-day option to purchase up to an additional $33.75M principal amount of notes

12/21/16

Sucampo Pharmaceuticals Inc. (Rockville, Md.)

Convertible senior notes offering

N/A

$260.00

Sucampo priced $260M in aggregate principal amount of 3.25% convertible senior notes due 2021 in a private placement to qualified institutional buyers; Sucampo also granted the initial purchaser of the notes a 13-day option to purchase up to an additional $40M to cover overallotments

12/22/16

Tetra Bio-Pharma Inc. (Ottawa, Ontario)

Private placement

5U

$1.00

Tetra Bio-Pharma is conducting a non-brokered private placement with Aphria Inc. of 5M units at $0.20 each for aggregate gross proceeds of $1M; each unit will consist of one common share and one non-transferable warrant, with a whole warrant entitling the holder to purchase one common share of the company at $0.26 per share for a period of three years following the closing date

12/7/16

Valneva SE (Lyon, France)

Private placement and share purchase

2.9S

$8.00

MVM Life Science Partners LLP acquired a 7.5% holding in the company through a combined private placement and share purchase; Valneva issued about 2.9M primary shares for proceeds of €7.5M (US$8M)

12/2/16

Valneva SE (Lyon, France)

Private placement

2.9S

$7.80

Valneva issued about 2.9M new ordinary shares to funds managed by MVM by way of a private placement without preferential subscription rights; the placement results in aggregate proceeds of €7.5M (US$7.8M)

12/19/16

VBI Vaccines Inc. (Cambridge, Mass.)

Private placement and loan

3.475S

$23.60

VBI Vaccines raised $23.6M in concurrent equity and debt financing transactions with Perceptive Advisors; VBI sold 3.475M of its common shares at $3.05 per share for total gross proceeds of approximately $10.6M; additionally, Perceptive Advisors increased its current credit agreement with VBI by funding an additional $13M in secured debt

12/7/16


Notes

This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Loan money is included in the total only when it is drawn down, if disclosed.

Currency conversions are based on exchange rates at the time of the deal.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

N/A = Not applicable; ND = Not disclosed.

This chart includes only biotech companies that develop therapeutics.